Despite the use of laser therapy as the current treatment for retinopathy of prematurity (ROP), the administration of ranibizumab is recognized as a promising alternative treatment for ROP despite the current use of laser therapy. Therefore, this systematic review aimed to systematically analyze the effectiveness of different ranibizumab dosage.
Methods
A literature search of PubMed, Cochrane, and ScienceDirect was conducted for studies including infants with ROP, using intravitreal injection of ranibizumab (IVR) as primary monotherapy, and reporting ROP regression and recurrence. All studies were required to be written in English-language and published in the last ten years. The selection process followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines.
Results
A total of ten studies were reviewed, including three randomized controlled trials, five retrospectives, and two case series. Furthermore, 549 patients and 867 eyes in the treatment group were evaluated, examining various stages of ROP and different therapeutic methods. All studies reported ROP regression, ranging from 68.9% to 100%, while 80% reported ROP recurrence following IVR.
Conclusion
Intravitreal injections of ranibizumab were effective in improving ROP outcomes. Meanwhile, lower doses of IVR provided comparable therapeutic benefits to the higher dose, potentially with fewer side effects.
KimJSFawziAKovachJL, et al.Retinopathy of prematurity. In: RapuanoCJStoutJTMcCannelCA (eds). Basic and clinical science course. San Francisco: American Academy of Ophthalmology, 2024, pp. 193–213.
3.
ChiangMFQuinnGEFielderAR, et al.International classification of retinopathy of prematurity, third edition. Ophthalmology2021; 128(10): e51–e68.
4.
Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Arch Ophthalmol1988; 106(4): 471e479.
5.
GoodWVEarly Treatment for Retinopathy of Prematurity Cooperative Group. Early treatment for retinopathy of prematurity cooperative group. Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc2004; 102: 233–250.
6.
StahlALeporeDFielderA, et al.Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet2019; 394(10208): 1551–1559.
7.
WongRKHubschmanSTsuiI. Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina2015; 35(4): 675–680.
8.
HuangQZhangQFeiP, et al.Ranibizumab injection as primary treatment in patients with retinopathy of prematurity: anatomic outcomes and influencing factors. Ophthalmology2017; 124(8): 1156–1164.
9.
PageMJMcKenzieJEBossuytPM, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ2021; 372: n71.
10.
OuzzaniMHammadyHFedorowiczZ, et al.Rayyan-a web and mobile app for systematic reviews. Syst Rev2016; 5(1): 1–10.
11.
ChenSNLianIHwangYC, et al.Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab. Retina2015; 35(4): 667–674.
12.
TawfikGMShaheinEADabourSA, et al.Comparison of intravitreal injection of ranibizumab versus bevacizumab for treatment of type 1 and aggressive retinopathy of prematurity in rural Egypt. A randomized clinical trial. BMJ Open Ophthalmol2022; 7: e001173.
13.
ErolMKCobanDTSariES, et al.Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity. Arq Bras Oftalmol2015; 78(6): 340–343.
14.
StahlAKrohneTUEterN, et al.Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial. JAMA Pediatr2018; 172(3): 278–286.
15.
WardatiHJKhadijahMNurul-FarhanaM, et al.Comparison of intravitreal ranibizumab and laser photocoagulation in the treatment of type I retinopathy of prematurity in Malaysia: a one-year follow-up study. Cureus2024; 16(7): e63712.
16.
MenkeMNFrammeCNelleM, et al.Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease. BMC Ophthalmol2015; 15: 20.
17.
WellsGSheaBO’ConnellD, et al.The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Ottawa, ON: Ottawa Hospital Research Institute, 2021. [cited 2024 Sep 2]. Available from. https://www.ohri.ca//programs/clinical_epidemiology/oxford.asp
18.
SterneJACSavovićJPageMJ, et al.Rob 2: a revised tool for assessing the risk of bias in randomized trials. BMJ2019; 366: 1–8.
HaritonELocascioJJ. Randomised controlled trials—the gold standard for effectiveness research. BJOG2018; 125(13): 1716.
21.
SanctisVDSolimanATDaarS, et al.Retrospective observational studies: lights and shadows for medical writers. Acta Biomed2022; 93(5): e2022319.
22.
LingKPLiaoPJWangNK, et al.Rates and risk factors for recurrence of retinopathy of prematurity after laser or intravitreal anti-vascular endothelial growth factor monotherapy. Retina2020; 40(9): 1793–1803.
23.
WuWCShihCPLienR, et al.Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity. Retina2017; 37(4): 694–701.
24.
ZouQZhuYQZhangFJ, et al.Efficacy evaluation of intravitreal ranibizumab therapy for three types of retinopathy of prematurity. Int J Ophthalmol2022; 15(5): 753–759.
25.
AldebasiTGumaMABashirR, et al.Intravitreal ranibizumab injection for the treatment of retinopathy of prematurity. Med Princ Pract2019; 28(6): 526–532.
26.
AhmedISHadiAMHassanHH. Efficacy of ultra-low-dose (0.1 mg) ranibizumab intravitreal injection for treatment of prethreshold type 1 retinopathy of prematurity: a case series. Eur J Ophthalmol2020; 30(1): 40–47.
27.
ChenYWangSChenS, et al.Appropriate dose of intravitreal ranibizumab for ROP: a retrospective study. BMC Ophthalmol2022; 22(1): 271.
28.
Mintz-HittnerHAKennedyKAChuangAZ, et al.Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med2011; 364: 603–615.
29.
AveryRLCastellarinAASteinleNC, et al.Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol2014; 98(12): 1636–1641.
30.
StahlABründerMLagrèzeWA, et al.Ranibizumab in retinopathy of prematurity – one‐year follow‐up of ophthalmic outcomes and two‐year follow‐up of neurodevelopmental outcomes from the care‐rop study. Acta Ophthalmol2022; 100(1): e91–e99.
31.
TianYFanZZengX, et al.Long-term follow-up of the cognitive function in children after intravitreal ranibizumab for retinopathy of prematurity. Graefe S Arch Clin Exp Ophthal2024; 262(10): 3117–3124.
32.
DiggikarSGurumoorthyPTrifP, et al.Retinopathy of prematurity and neurodevelopmental outcomes in preterm infants: a systematic review and meta-analysis. Front Pediatr2023; 11: 1055813.
33.
LinghuDChengYZhuX, et al.Comparison of intravitreal anti-VEGF agents with laser photocoagulation for retinopathy of prematurity of 1,627 eyes in China. Front Med2022; 9: 911095.
34.
LiZZhangYLiaoY, et al.Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in type-1 and threshold retinopathy of prematurity (ROP). BMC Ophthalmol2018; 18(1): 19.
35.
IsaacMMireskandariKTehraniN. Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser. J AAPOS2015; 19: 140–144.
36.
HarderBCSchlichtenbredeFCvon BaltzS, et al.Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am J Ophthalmol2013; 155: 1119.e1–1124.e1.
